Efficacy and Safety of a Modified Ublituximab Regimen (ENHANCE) (P11-1.009)
To describe a modified dosing regimen in the ENHANCE study evaluating ublituximab in participants with relapsing multiple sclerosis (RMS) who are treatment-naïve or transitioning from other disease modifying therapies.
Authors
- John Scagnelli
- Craig Herrman
- Emily Riser (ORCID: https://orcid.org/0000-0002-0486-2594)
- Martin Belkin
- Jonathan Calkwood
- Hari P. Miskin
- John Foley (ORCID: https://orcid.org/0000-0003-0431-7067)
- Edward Fox (ORCID: https://orcid.org/0000-0003-0347-1839)
- Tamara Miller
- B. Singer (ORCID: https://orcid.org/0000-0001-6875-7374)
- Derrick Robertson (ORCID: https://orcid.org/0000-0001-8993-0981)
- April Erwin
- Gabriel Pardo (ORCID: https://orcid.org/0000-0002-2207-3708)
- Peter Sportelli
- Christopher LaGanke
- Christopher R. Rowland (ORCID: https://orcid.org/0000-0003-0228-4054)
- Peiqing Qian (ORCID: https://orcid.org/0000-0003-4774-7788)
- Salvatore Napoli (ORCID: https://orcid.org/0000-0002-7713-7983)
- Chris Garner
- Theodore R. Brown
- Sibyl Wray
Institutions
- University of South Florida (US)
- Oklahoma Medical Research Foundation (US)
- New England Center for Children (US)
- Rocky Mountain Multiple Sclerosis Clinic (US)
- Michigan Institute for Neurological Disorders (US)
- HOPE Clinic (US)
- Velocity Clinical Research (United States) (US)
- Center for Innovation (US)
- CDG Therapeutics (United States) (US)
- Associates in Neurology (US)
- Evergreen Health Medical Center (US)
- North Central College (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211930
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00